Negev Labs develops neuroplastogens, a new class of non-hallucinogenic compounds that enhance neuroplasticity and cellular resilience, targeting a range of psychiatric and neurological disorders. By leveraging the cellular mechanisms of psychedelics, these compounds can be rapidly advanced through human proof-of-concept trials, facilitating scalable therapeutic solutions.
Funding
$4.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many psychiatric and neurological disorders lack effective treatments that can enhance neuroplasticity and cellular resilience without causing hallucinogenic side effects. Traditional approaches often have limited efficacy or significant adverse effects, leaving a substantial unmet need for novel therapeutic interventions.
Solution
Negev Labs is developing a new class of non-hallucinogenic compounds called neuroplastogens, designed to enhance neuroplasticity and cellular resilience. These compounds leverage the cellular mechanisms of psychedelics to promote therapeutic effects without the associated psychoactive effects. This approach allows for rapid advancement through human proof-of-concept trials, facilitating the development of scalable therapeutic solutions for a range of psychiatric and neurological disorders, as well as potential applications in ophthalmology. By focusing on non-hallucinogenic alternatives, Negev Labs aims to overcome the limitations of first-generation psychedelic drug candidates and provide safer, more accessible treatments.
Target Audience
The primary target audience includes individuals suffering from psychiatric and neurological disorders, as well as pharmaceutical companies seeking novel therapeutic candidates.
Features
- Non-hallucinogenic compounds that enhance neuroplasticity
- Targets a range of psychiatric, neurological, and ophthalmological disorders
- Leverages cellular mechanisms of psychedelics without psychoactive effects
- Designed for rapid advancement through human proof-of-concept trials
- Aims to create scalable therapeutic solutions